San Diego, CA, United States of America

Eugene Tu

This inventor holds 64 USPTO granted patents and 21 published patent applications, plus 8 CIPO patents and 8 EPO patents, primarily in Nucleic Acid Sequencing (CPC class C12Q). Top assignees: Nanogen, Inc., Biological Dynamics, Inc., Omniome, Inc.. Active years: 1997-2023.

USPTO Granted Patents = 64 

% Patents Active = 81.3


 

Average Co-Inventor Count = 3.8

ph-index = 21

Forward Citations = 3,547(Granted Patents)

Forward Citations (Not Self Cited) = 3,329(Dec 10, 2025)


Inventors with similar research interests:


Company Filing History:


Years Active: 1997-2023

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Nucleic Acid Sequencing
Skin Perfusion Monitoring
Electrochemical Nanosensors
Cell Sorting
Chiral Object Manipulation
Oligonucleotide Analysis
Biomolecule Detection
Self-Addressable Systems
64 patents (USPTO):Explore Patents

**Title: The Innovative Journey of Eugene Tu**

Introduction:

Eugene Tu, a visionary inventor based in San Diego, CA, has made significant contributions to the world of innovation through his groundbreaking work in various fields.

Latest Patents:

Eugene Tu holds several patents in diverse areas, showcasing his versatility and creativity in inventing new solutions to complex problems.

Career Highlights:

Throughout his illustrious career, Eugene Tu has demonstrated a keen ability to push the boundaries of what is possible. His innovative spirit has led to the development of cutting-edge technologies that have revolutionized industries.

Collaborations:

Eugene Tu has collaborated with leading experts in the field, fostering a culture of innovation and excellence. His partnerships have resulted in the creation of groundbreaking inventions that have left a lasting impact on society.

Conclusion:

In conclusion, Eugene Tu's relentless pursuit of innovation and his passion for creating a better future have solidified his position as a pioneering inventor in

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…